In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumor xenografts

Xie, Huan; Wang, Zheng Jim; Bao, Ande; Goins, Beth; Phillips, William T.

doi:10.1016/j.ijpharm.2010.06.005

Cited by 101 publications

(86 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the tumor environment, a similar aggregation can occur that can explain the nondegradation of the NPs observed in the tumor. The results presented here show moderate tumor accumulation via passive targeting, which are comparable to results described by other groups in the literature [28][29][30][31]. However, while tumor uptake is quite similar, uptake in the RES organs is much higher in those studies, which could be problematic for future clinical translation.…”

Section: Discussionsupporting

confidence: 83%

⁶⁸ Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy

Bouziotis

Stellas

Thomas

et al. 2017

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Aim: The aim of this study was to develop a dual-modality positron emission tomography/magnetic resonance (PET/MR) imaging probe by radiolabeling gadolinium-containing AGuIX derivatives with the positron-emitter Gallium-68 (68Ga). Materials & methods: AGuIX@NODAGA nanoparticles were labeled with 68Ga at high efficiency. Tumor accumulation in an appropriate disease model was assessed by ex vivo biodistribution and in vivo PET/MR imaging. Results: 68Ga-AGuIX@NODAGA was proven to passively accumulate in U87MG human glioblastoma tumor xenografts. Metabolite assessment in serum, urine and tumor samples showed that 68Ga-AGuIX@NODAGA remains unmetabolized up to at least 60 min postinjection. Conclusion: This study demonstrates that 68Ga-AGuIX@NODAGA can be used as a dual-modality PET/MR imaging agent with passive accumulation in the diseased area, thus showing great potential for PET/MR image-guided radiation therapy.

show abstract

Section: Discussionsupporting

confidence: 83%

⁶⁸ Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy

Bouziotis

Stellas

Thomas

et al. 2017

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

“…They can be manufactured with size ranges (60-400 nm) that can accumulate in tumors via the enhanced permeability and retention effect, which is attributed to the leaky nature of tumor vessels. 4 However, our previous research found that accumulation of nanoshells in solid tumors via the enhanced permeability and retention effect is very limited when they are injected intravenously, [5][6][7] which hinders the efficacy of subsequent photothermal ablation, and is a major challenge for this therapy.…”

Section: Introductionmentioning

confidence: 99%

Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells

Xie¹,

Goins²,

Bao³

et al. 2012

IJN

Self Cite

View full text Add to dashboard Cite

Background: Gold nanoshells are excellent agents for photothermal ablation cancer therapy and are currently under clinical trial for solid tumors. Previous studies showed that passive delivery of gold nanoshells through intravenous administration resulted in limited tumor accumulation, which represents a major challenge for this therapy. In this report, the impact of direct intratumoral administration on the pharmacokinetics and biodistribution of the nanoshells was systematically investigated. Methods: The gold nanoshells were labeled with the radionuclide, copper-64 ( 64 Cu). Intratumoral infusion of 64 Cu-nanoshells and two controls, ie, 64 Cu-DOTA (1,4,7,10-tetraazaciclododecane-1,4,7,10-tetraacetic acid) and 64 Cu-DOTA-PEG (polyethylene glycol), as well as intravenous injection of 64 Cu-nanoshells were performed in nude rats, each with a head and neck squamous cell carcinoma xenograft. The pharmacokinetics was determined by radioactive counting of serial blood samples collected from the rats at different time points post-injection. Using positron emission tomography/computed tomography imaging, the in vivo distribution of 64 Cu-nanoshells and the controls was monitored at various time points after injection. Organ biodistribution in the rats at 46 hours was analyzed by radioactive counting and compared between the different groups. Results:The resulting pharmacokinetic curves indicated a similar trend between the intratumorally injected agents, but a significant difference with the intravenously injected 64 Cu-nanoshells. Positron emission tomography images and organ biodistribution results on rats after intratumoral administration showed higher retention of 64 Cu-nanoshells in tumors and less concentration in other healthy organs, with a significant difference from the controls. It was also found that, compared with intravenous injection, tumor concentrations of 64 Cu-nanoshells improved substantially and were stable at 44 hours post-injection. Conclusion: There was a higher intratumoral retention of 64 Cu-nanoshells and a lower concentration in other healthy tissues, suggesting that intratumoral administration is a potentially better approach for nanoshell-based photothermal therapy.

show abstract

mentioning

confidence: 99%

“…Nanoscale imaging agents, tumor specific nanosensors, and highly effective therapeutic nanoprobes, derived from radioactive metallic nanoparticles and engineered nanomaterials, have already demonstrated "proof of concept" for diagnosis, imaging and treatment of many cancers at the cellular and molecular levels (13,14). While specific nanoparticles can indivi-dually act as imaging or therapy agents, radioactive gold nanoparticles will provide unprecedented dual imaging and therapeutic ("theranostic") capabilities for use in the development of a new generation of cancer diagnostic and therapeutic agents (15)(16)(17)(18)(19).…”

mentioning

confidence: 99%

Laminin receptor specific therapeutic gold nanoparticles ( ¹⁹⁸ AuNP-EGCg) show efficacy in treating prostate cancer

Shukla

Chanda

Zambre

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

233

186

View full text Add to dashboard Cite

Systemic delivery of therapeutic agents to solid tumors is hindered by vascular and interstitial barriers. We hypothesized that prostate tumor specific epigallocatechin-gallate (EGCg) functionalized radioactive gold nanoparticles, when delivered intratumorally (IT), would circumvent transport barriers, resulting in targeted delivery of therapeutic payloads. The results described herein support our hypothesis. We report the development of inherently therapeutic gold nanoparticles derived from the Au-198 isotope; the range of the 198 Au β-particle (approximately 11 mm in tissue or approximately 1100 cell diameters) is sufficiently long to provide cross-fire effects of a radiation dose delivered to cells within the prostate gland and short enough to minimize the radiation dose to critical tissues near the periphery of the capsule. The formulation of biocompatible 198 AuNPs utilizes the redox chemistry of prostate tumor specific phytochemical EGCg as it converts gold salt into gold nanoparticles and also selectively binds with excellent affinity to Laminin67R receptors, which are over expressed in prostate tumor cells. Pharmacokinetic studies in PC-3 xenograft SCID mice showed approximately 72% retention of 198 AuNP-EGCg in tumors 24 h after intratumoral administration. Therapeutic studies showed 80% reduction of tumor volumes after 28 d demonstrating significant inhibition of tumor growth compared to controls. This innovative nanotechnological approach serves as a basis for designing biocompatible target specific antineoplastic agents. This novel intratumorally injectable 198 AuNP-EGCg nanotherapeutic agent may provide significant advances in oncology for use as an effective treatment for prostate and other solid tumors.nanoradiotherapy | tumor metastases | localized therapy | polyphenols | cellular targeting R ecent data have confirmed that the incidence of prostate cancer is the highest among all estimated new cancer cases in American males, nearly double that of lung cancer (1). Globally, prostate cancer continues to be the second leading cause of cancer-related death in men (1). A detailed study involving 77,000 North Americans has shown that 10 y of regular prostate specific antigen (PSA) screening did not save a significant number of lives (2). Therefore, developments of new therapeutic protocols that provide effective control of the growth and propagation of prostate tumors have gained considerable clinical significance in the care and treatment of prostate cancer patients (3). The latest clinical trials on human prostate cancer patients using various experimental drugs further attest that shrinking prostate tumor sizes led to more than doubled survival in 70-80% of patients with aggressive cancers (3). Although a plethora of therapeutic approaches, which include utility of cytotoxic drugs (paclitaxel, estramustine, carboplatin, and doxorubicin) are currently in clinical practice, unfortunately, none of these chemotherapeutic agents offer a clinically efficient, affordable, and toxicologically safe regimen...

show abstract

In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumor xenografts

Cited by 101 publications

References 27 publications

⁶⁸ Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy

⁶⁸ Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy

Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells

Laminin receptor specific therapeutic gold nanoparticles ( ¹⁹⁸ AuNP-EGCg) show efficacy in treating prostate cancer

Contact Info

Product

Resources

About

In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumor xenografts

Cited by 101 publications

References 27 publications

68 Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy

68 Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy

Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells

Laminin receptor specific therapeutic gold nanoparticles ( 198 AuNP-EGCg) show efficacy in treating prostate cancer

Contact Info

Product

Resources

About

⁶⁸ Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy

⁶⁸ Ga-Radiolabeled AGuIX Nanoparticles as Dual-Modality Imaging Agents for PET/MRI-Guided Radiation Therapy

Laminin receptor specific therapeutic gold nanoparticles ( ¹⁹⁸ AuNP-EGCg) show efficacy in treating prostate cancer